Chiromics LLC

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Chiromics has developed a novel approach to harness temporal and innate pain response elements through positive allosteric modulation of the endogenous ligand interaction with the mu opioid receptor. To this end, we have developed patent-protected, novel first-in-class compounds with in vivo POC and safety.
The discovery of Chiromics’ lead compounds was enabled by our unique chemical-space compound collection. Generated by cutting-edge chemistry from the laboratory of David MacMillan at Princeton, this library works in synergy with our proprietary Affinity Screening Mass Spectroscopy technology.
Chiromics was founded by David MacMillan (Distinguished University Professor of Chemistry at Princeton University) and Paul Reider (Worldwide VP, Amgen (retired)) to bring disruptive technologies to the drug discovery process.
We are looking for a partner to advance our lead compounds into the clinic for non-opioid mediated pain relief and as a potential treatment for opioid addiction.
Company Type:
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2010
Main Therapeutic Focus:
Lead Product in Development:
Positive Allosteric Modulator of MOR
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker